Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.
Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA. Palfi S, et al. Among authors: fenelon g. Lancet. 2014 Mar 29;383(9923):1138-46. doi: 10.1016/S0140-6736(13)61939-X. Epub 2014 Jan 10. Lancet. 2014. PMID: 24412048 Clinical Trial.
Can nicotine be used medicinally in Parkinson's disease?
Thiriez C, Villafane G, Grapin F, Fenelon G, Remy P, Cesaro P. Thiriez C, et al. Among authors: fenelon g. Expert Rev Clin Pharmacol. 2011 Jul;4(4):429-36. doi: 10.1586/ecp.11.27. Expert Rev Clin Pharmacol. 2011. PMID: 22114853 Review.
[Biotherapies and Parkinson's disease].
Cesaro P, Fenelon G, Remy P. Cesaro P, et al. Among authors: fenelon g. Rev Neurol (Paris). 2009 Nov;165(11):857-62. doi: 10.1016/j.neurol.2009.03.017. Epub 2009 May 31. Rev Neurol (Paris). 2009. PMID: 19487002 Review. French.
High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study.
Villafane G, Thiriez C, Audureau E, Straczek C, Kerschen P, Cormier-Dequaire F, Van Der Gucht A, Gurruchaga JM, Quéré-Carne M, Evangelista E, Paul M, Defer G, Damier P, Remy P, Itti E, Fénelon G. Villafane G, et al. Among authors: fenelon g. Eur J Neurol. 2018 Jan;25(1):120-127. doi: 10.1111/ene.13474. Epub 2017 Oct 23. Eur J Neurol. 2018. PMID: 28960663 Clinical Trial.
Outcome of bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease: correlation with intra-operative multi-unit recordings but not with the type of anaesthesia.
Lefaucheur JP, Gurruchaga JM, Pollin B, von Raison F, Mohsen N, Shin M, Ménard-Lefaucheur I, Oshino S, Kishima H, Fénelon G, Rémy P, Cesaro P, Gabriel I, Brugières P, Keravel Y, Nguyen JP. Lefaucheur JP, et al. Among authors: fenelon g. Eur Neurol. 2008;60(4):186-99. doi: 10.1159/000148246. Epub 2008 Jul 31. Eur Neurol. 2008. PMID: 18667827 Clinical Trial.
218 results